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Abstract

Porphyrins are organic compounds that continue to attract much theoretical interest, and have been
called the “pigments of life”. They have a wide role in photodynamic and sonodynamic therapy, along
with uses in magnetic resonance, fluorescence and photoacoustic imaging. There is a vast range of
porphyrins that have been isolated or designed, but few of them have real clinical applications. Due to
the hydrophobic properties of porphyrins, and their tendency to aggregate by stacking of the planar
molecules they are difficult to work with in aqueous media. Therefore encapsulating them in
nanoparticles (NPs) or attachment to various delivery vehicles have been used to improve delivery
characteristics. Porphyrins can be used in a composite designed material with properties that allow
specific targeting, immune tolerance, extended tissue lifetime and improved hydrophilicity. Drug
delivery, healing and repairing of damaged organs, and cancer theranostics are some of the medical
uses of porphyrin-based nanocomposites covered in this review.

Keywords

Porphyrin, Nanoparticle, Nanocomposite, Drug delivery, Theranostics

1. Introduction

In the past, intravenous injection of pharmaceuticals containing insoluble suspensions was considered
impossible due to the danger of embolisms. Nowadays, improvements in nanoparticle (NP)
suspensions including nano-drugs has increased the therapeutic index. Nano-drugs with improved
activity, reduced toxicity and the ability to target the diseased tissues have emerged [[1], [2], [3]].
However, many nanoparticles are still solid macromolecular constructions, which are too disperse, not

necessarily polymers, and generally less than 200 nm in diameter [1,[4], [5], [6]]. Since the late
seventies, the use of nanoparticles as drug targeting vehicles has faced the problem of the lack of
the biodegradability of polymers [7]. Development of nano-vehicles depends on polymers with good
biocompatibility and biodegradability properties, which has been helped by the introduction
of albumin [8], polyalkyl cyanoacrylate [9], polylactate and glycolate [10], lipids in solid form [11], and
chitosan [12] NPs. Overall these nanovehicles were proposed for the treatment of different diseases of
the liver or reticuloendothelial system (as well as cancer or infectious disease) because of the ability to
concentrate in these tissues. The biodistribution of NPs is goverened by the
natural opsonization process that appears after intravenous injection, and the next level was specific
targeting to tissues and organs [13,14].
It is worth mentioning that the targeting of NPs via specific antibodies that recognize cancer cells was
utilized in the early eighties [15]. Recent bioconjugation methods, like the Huisgen 1,3dipolar cycloaddition reaction (named “click chemistry”), are suitable for NP construction [16].
Targeted delivery is considered the most likely option to improve the treatment of many diseases.
Targeted delivery gives us three valuable advantages that traditional systemic delivery lacks: (1) the
therapeutics will act at the intended action site, limiting off-target effects, including the damaging sideeffects of chemotherapy; (2) the lower dose needed with targeted delivery can better focus the
therapeutic agent to the target site, and reduce systemic side effects; (3) targeted delivery can
transport the therapeutics to places that are not easily accessible by traditional drugs. The first attempt
at improving delivery were carriers attached to antibodies. Two FDA-approved examples
were Brentuximab vedotin (Adcetris) and Trastuzumab emtansine (Kadcyla)], while some others are
still in clinical testing [17]. However, some limitations of this approach cause problems, such as
structural heterogeneity, inconsistent preparation, and restricted solubility [17,18]. Drugs that contain
antibodies are generally useful only in some cases. Additionally, other NP delivery vehicles (such
as liposomes, polymer based NPs, metal based NPs, and protein based NPs), have the potential to carry
out more effective and more reliable delivery due to encapsulating therapeutic cargos within the
particle with a higher cargo to carrier ratio [3,16].
Porphyrins belong to a class of heterocyclic macrocycles. These organic compounds are constructed
from four conjugated pyrrole rings arranged in a circle. The pyrrole α-carbon atoms are connected
with methylene bridges [19]. Porphyrins have a total of 26 π-electrons, of which 18 π-electrons are in a
planar, continuous macrocycle [20]. The basic chemical structure of porphyrin and its main family
members are summarized in Fig. 1.

Fig. 1. Basic chemical structure of porphyrins and the main family members.

The understanding of porphyrin structures has advanced appreciably in recent years, and many
publications have described detailed structures for porphyrin and metalloporphyrin molecules and
their different roles in biomedical applications. Generally, porphyrins are a class of tetrapyrrole
macrocycles with a 1-D or 2-D or sometimes 3-D skeleton. By replacing the α, β and other carbon
atoms of porphyrins, by nitrogen atoms and the other alternatives, their properties can change
dramatically, and also their biomedical applications. In addition, aspects of the chemistry of porphyrins
are related to their acting as ligands in coordination complexes, depending on their structural
properties which are controlled by bond angles and bond distances, as well as the nature of the metal
and also the presence of functional groups. Generally, by using members of the first row of transition
metals in the structure of porphyrins, toxicity is decreased to the minimum, however some second and
third row transition metals such as Pt, Pd and Ru also have low cellular toxicity. By using amine-based
ligands or linkers as the substituents, the biomedical applications of these compounds
in photodynamic therapy, drug delivery and gene delivery are widened. However, carboxy-based
linkers are also efficient for drug delivery, due to their potential bonding affinity with several drugs
via hydrogen bonds [[21], [22], [23], [24]]. In this review article, a logical perspective about the
relationship between the structural chemistry of porphyrins and their biomedical applications is
presented.
Recently, porphyrin-based nanomaterials have received much attention due to various photophysical
and photochemical properties of porphyrins [25,26]. The porphyrins can be extended to form other
molecules using a central metalation process, which further tunes the photophysical properties of the
porphyrins. Although the porphyrin family is famous for their light-mediated generation of highly
reactive oxygen species, especially singlet oxygen, most porphyrin-based chemicals also have good
fluorescence properties and photoacoustic properties, which make them potential candidates for
simultaneous imaging/therapy applications called “theranostics” [[27], [28], [29]]. In this review, we

summarize the latest advances in preparation and delivery of porphyrin nanosystems and their
biomedical applications.

2. Cancer theranostics using porphyrin-based nanomaterials
2.1. Cancer theranostics

Investigators have been interested in porphyrins and the related compounds for their powerful
photosensitizing properties, their ability to selectively accumulate inside tumors and other abnormal
tissues and cells, and their ability to remain inside tissues for long periods. These properties have
enabled them to be used in biomedical applications from imaging for diagnosis (like fluorescence and
magnetic resonance imaging (MRI)) to therapeutic uses (e.g. photodynamic, sonodynamic,
boron neutron capture [30], and radiation therapy (RT)). Among them, PDT (photodynamic therapy),
SDT (sonodynamic therapy) and BNCT (boron neutron capture therapy) are binary cancer therapies
that require the simultaneous localization of the compound to the targeted tissue and the local
(spatially confined) application of physical energy such as light (in PDT), ultrasound (in SDT) or a lowenergy neutron beam (in BCNT). Therefore, porphyrins and their derivatives can be used in therapies
that have potential for local control of tumors with fewer side effects than surgery or other cancer
therapies (like radiotherapy, and chemotherapy). Also, since porphyrins are effective as metal
chelators, they can transport metallic radioisotopes for use in cancer radiotherapy. Moreover, most
porphyrins are hydrophobic and prefer an aggregated form, which may affect the therapeutic outcome
resulting in a reduction in singlet O2 generation and lower fluorescence quantum yields; therefore,
many porphyrin nanocarriers have been investigated as photosensitizers for PDT applications [30].
Photofrin is one of the porphyrin derivatives used as a photosensitizing agent in cancer therapy.
Another porphyrin derivative is Visudyne (benzoporphyrin derivative mono acid ring A), which has
been approved as a pharmacological agent in ophthalmology by the Food and Drug Administration of
United States (FDA). However, porphyrins and related derivatives still have the limitation of low
aqueous solubility, making them hydrophobic and prone to aggregate. This aggregation is the main
reason for the decrease in therapeutic efficacy, because generally only the monomeric species are
photochemically active. However, porphyrins prefer to accommodate in tumors because of the
unusual properties of cancer neovasculature. The highly permeable endothelium of tumor capillaries
and the deficiency of lymphatic drainage in tumors allows selective accumulation in tumors over time
after intravenous injection. However the selectivity of porphyrins for tumors is variable, and porphyrin
cytotoxicity has to be considered that could affect healthy cells. Recently, with the advances made in
nanotechnology for biomedical applications, a variety of NPs (i.e. inorganic and hybrid
nanoparticles, liposomes, and polymeric micelles) have been applied to incorporate porphyrins, which
generally improves their behavior in aqueous media. These nanocarriers should have suitable
biocompatibility, biodegradability and should allow simple preparation and modification for the
desired goals [30]. Porphyrins loaded inside NPs could solve some of the difficulties that have been
mentioned above, and provide improved diagnostic and therapeutic properties. The use of porphyrins
as multimodality imaging agents can impact the modern drive towards personalized medicine,
monitoring and predicting the success of therapy, and yielding a better comprehension of disease
states [30].

New porphyrin derivatives and their immobilization on iron oxide NPs were found to provide
promising nanotools for PDT. Specifically, a zinc porphyrin derivative, ZnPR-COOH, was synthesized,
characterized and immobilized onto prior synthesized iron oxide NPs via oleylamine. Characterization
of this novel nanosystem (ZnPR-IONP) was achieved using different methods, such as UV–
Vis spectrophotometry, fluorescence, X-ray photoelectron spectroscopy (XPS) and transmission
electron microscopy (TEM). To explore the potential of the photosensitizer for PDT they quantified the
singlet oxygen yield of ZnPR-IONP and the free ligand ZnPR-COOH, using 9, 10-anthracenedipropionic
acid (ADPA) [31]. The results showed an increased singlet oxygen quantum yield after the porphyrin
was attached to IONP (ZnPR-IONP). Furthermore, another porphyrin derivative called PR-TRIS3OH,
combining various polar groups (TRIS), for improved water solubility was synthesized and immobilized
in nanosystems. The singlet oxygen yield was measured, and was similar to ZnPR-COOH/ZnPR-IONP,
and more than two-fold higher in the form of PRTRIS-IONP nanoparticles. The impressive singlet
oxygen yield of PRTRIS-IONP along with its water solubility, suggests that these new nanotools could be
used in PDT.
Although iron oxide based nanosystems that can be used PDT have been known for a decade, the
production of new water-soluble porphyrin-based ligands has allowed iron oxide nanoparticles (IONPs)
to be investigated for new medical uses. A zinc porphyrin derivative containing a phenoxy and three
phenyl groups, with a carboxylic acid group at the meso location, was produced (ZnPR-COOH) and
attached to the IONP surface to enhance the water-solubility of the NPs (ZnPR-IONPs).
The hydrophilic porphyrin derivative possessed three TRIS groups (PRTRIS3OH). The ligand with high
water solubility was immobilized on the IONPs surface to produce water stable NPs. The
photosensitizer drugs and the NP conjugate were characterized, and the good singlet oxygen yield
suggested they could be a candidate for PDT of cancer [32].
Gemcitabine hydrochloride is a chemotherapeutic drug with FDA-approval, used in the treatment of
various cancers. Gemcitabine suffers from several problems. Firstly, it has a short in vivo half-life
(about 8–17 min), secondly, it is rapidly excreted by the kidneys, and thirdly, its poor membrane
permeability, all taken together suggest a nano-delivery method would be advantageous. Penon and
coworkers [33] prepared periodic mesoporous organosilica NPs (PMOs) for light-activated for delivery
of gemcitabine for cancer treatment. They used porphyrins as photosensitizers which were
incorporated inside the PMO pores. Additionally, the ability of gemcitabine to be loaded into the
mesoporous structure was investigated. They used both one-photon, and two-photon activation
depending on the photosensitizer structure and its aggregation state. Ethylene-based PMOs were
covalently attached to a tetrasilylated porphyrin (PS1) and the resulting J-aggregates in the
mesostructure were suitable for two-photon PDT. The researchers found that the monosilylated
porphyrin (PS2) did not form J-aggregates, although it could mediate one photon PDT. Synergistic
cancer cell killing was observed by two-photon excited PDT plus gemcitabine delivery.
The commercially available tetra-amino porphyrin (PSa) was monosilylated by
isocyanatopropyltriethoxysilane [33] and together with the tetrasilylated compound [34] formed from
aminophenylporphyrin (PSb) provided EPMO (ethylene-based periodic mesoporous organosilica) NPs
by a sol-gel process using bis-(triethoxysilyl)ethane and cetyltrimethylammonium bromide (CTAB). Cocondensation of bis-(triethoxysilyl)ethane gave the silylated photosensitizers PS1 or PS2. These two

compounds produced PS1-EPMOs and PS2-EPMOs, respectively (Fig. 2). PDT was mediated by twophoton irradiation (800 nm) and combined with gemcitabine delivered via PS1-EPMOs NPs killed 62%
of the cells, showing potential efficacy for cancer treatment [35] (Fig. 3).

Fig. 2. PS1-EPMO and PS2-EPMO nanoparticles and their HRTEM micrographs, respectively (a and b). Images
exhibit usual mesoporosities. Photosensitizer precursors and their visible UV-spectrum via their NPs in EtOH (c
and d) [35].

Fig. 3. PS1, PS2 and their photosensitizer precursors Silylation (a and b). ethanephotosensitizer via PMO
nanoparticles production by Sol-gel (c). Functions of PMO nanoparticles for drug delivery
and photodynamic therapy (synergistic manner) (d) [35].

Despite the availability of many different kinds of nanoscale materials, only a small number can be
finely tuned for biomedical applications. It was shown that Zr(IV) incorporated in a porphyrinic MOF
(metal−organic framework) formed NPs that could be used for targeted PDT. Using a bottom-up
method, the MOF nanoparticle size can be precisely determined by tuning the functional motifs that
are used to construct the MOF components The type of porphyrinic linker employed in the metalorganic framework NPs affect the properties irrespective of their size. Moreover, the size-dependent
theranostic potential of these MOF clusters was studied in cancer cell models [36].
A porphyrinic Zr-MOF, called PCN-224 was suggested to be a strong candidate because of its good
chemical stability and possession of nanoporous channels, permitting effective diffusion of
photogenerated singlet oxygen [[37], [38], [39]]. The cubic phase of PCN-224 crystals would permit
isotropic growth of crystals, enabling clearer size determination without interference from other
variables (e.g., aspect ratio, and thickness) that would apply in a rod or a plate-shaped morphology
(Fig. 4).

Fig. 4. PCN-224 construction Image. (a) a cluster of Zr6 with the open formula of (Zr6O4 (OH) 4(H2O) 6(OH)
6(COO) 6), tetratopic linker with the open formula of (tetrakis (4-carboxyphenyl) porphyrin with the open
formula of (H2TCPP)), and image of PCN-224 as the 3D nanoporous framework. (b) A PCN-224 cubic unit and a
schematic image of spherical PCN-224 NPs in cubic units structure form, potential to make various sizes [36].

Penon et al. produced a porphyrin-based gold NP conjugate that was water soluble including an
antibody that recognizes the erbB2 receptor that is overexpressed on the surface of specific cancer
cells. They used a monophasic technique to produce NPs that could photo-generate a high quantity of
singlet oxygen, and the anti-erbB2 antibody bound to erbB2 receptors that were expressed on SK-BR-3
human breast cancer cells. The water-soluble, antibody-porphyrin NP conjugates were suggested to be
useful for targeted PDT [40].
2.1.1. X-PDT (X-ray-activated photodynamic therapy)
Popovich et al. [41] reported that a LuAG:Pr3+@SiO2-PpIX nanocomposite could mediate X-ray
activated PDT. It was prepared using a three-stage procedure: (a) the Lu3Al5O12:Pr3+ (LuAG:Pr3+) core
was by prepared by photo-induced precipitation, (b) the amorphous silica covering was applied by a
sol-gel method; and (c) protoporphyrin IX (PpIX) was chemically conjugated to the surface. The threelayered nanocomposite allowed X-ray activation of the Pr3+ to emit red luminescence; alternatively
the energy transfer non-radiatively excited PPIX to produce singlet oxygen. The fluorescent probe 3′-(paminophenyl) fluorescein was activated by reaction with singlet oxygen and confirmed the X-ray
activated PDT.

3. Different porphyrin-based nanoparticles

Nanoparticles can be engulfed by macrophages leading to accumulation inside the liver and the spleen
after intravenous administration leading to their rapid removal from the bloodstream. Covering the
NPs by poly (ethylene glycol) (PEG) extends the circulation time in the blood, leading to increased the
accumulation inside tumors. One study prepared a theranostic nanoconstruct via the coating of
Au nanoshells with poly (lactic acid) to form NPs that could be loaded with doxorubicin. They

subsequently attached a Mn-porphyrin to the Au shell using PEG linkers. The final construct showed
good colloidal stability and an extended blood circulation time because of the introduction of PEG.
Linking the Mn-porphyrin to the NP gave a high value of relaxivity (r1 value of 22.18 mM−1 s−1 of Mn3+),
desirable for magnetic resonance imaging of cancer. Irradiation with a near-infrared laser allowed
photothermal tumor destruction. The synergistic combination with doxorubicin chemotherapy
suggested this nanoconstruct could function as an anti-cancer theranostic agent [14,42].
A report from Jimenez et al. described a zinc porphyrin compound containing eight triethoxysilyl
groups attached by covalent bonds to mesoporous organosilica nanoparticles via the CuAAC-click
reaction. They have showed that this compound could mediate doxorubicin delivery and the imaging of
breast cancer cells by a two-photon imaging technique [43].

3.1. Liposomal porphyrins for cancer theranostics

Liposomes are spherical vesicles with an aqueous core surrounded a lipid bilayer. The use of liposomes
to load and transport porphyrin molecules is of interest due to their ability to increase the solubility
of PDT agents, and easy post-modification of the surface to enhance the accumulation and release in
the cancer cells [44]. It has been proven that the formation of liposomes could decrease the dark
cytotoxicity but enhance the PDT efficiency of the porphyrin, due to their ability to dissolve the
hydrophobic PDT drugs inside the lipid bilayer [45,46]. Liposomes were first demonstrated in 1960, and
are one of the few nanoparticle systems that have been successfully employed in clinical studies
[[47], [48], [49], [50]], showing their potential to be used for delivery of PDT drugs, especially
porphyrins [51,52].
Tedesco et al. [53] synthesized liposome-based zinc phthalocyanine incorporating a
nitrosyl ruthenium complex and using liposomes based on dipalmitoylphosphatidylcholine (DPPC) and
cholesterol. Their results showed a dramatic enhancement of the PDT effect against B16/F10
melanoma cells. The high efficiency of this system was explained by the interaction between the
excited zinc phthalocyanine and the nitrosyl ruthenium complex, leading to release of NO radicals due
to an electron transfer process which was enabled by the formation of the liposomes. Hiraka et al. [54]
prepared pH-sensitive liposomes using a combination of anionic and cationic lipids plus Fe-porphyrin.
The resulted liposomes showed remarkable PDT efficiency against MKN28 cells. Managa et al. [55]
investigated the photophysical properties of liposomes based on F127 polymer, Zn-porphyrin,
combined with graphene quantum dots (GQDs). The results indicated a synergistic effect of the GQDs
and the porphyrin on singlet oxygen generation, as well as the high stability of the nanoconstruct due
to π-π stacking. The formation of the liposomes led to enhanced cell uptake [56], and finally pHresponsive drug release due to changes in environmental pH [57].
The applications of porphyrin-based liposomes are not limited to PDT. One group of researchers
prepared a theranostic construct composed of porphyrin dyad nanoparticles (TPD NPs) to allow
magnetic resonance imaging (MRI) as well as PDT for cancer treatment. The liposomal NPs contained
two different porphyrins, a non-metal porphyrin lipid, and a conjugated Mn–porphyrin. The metal-free
porphyrin acted as a photosensitizer for PDT, while the Mn–porphyrin acted as a contrast agent for
MRI. The theranostic porphyrin dyad nanoparticles (~60 nm) could accumulate inside tumors and were
taken up by the tumor cells. 24 h after intravenous injection, MRI images of the tumor area were much

brighter than the surrounding healthy tissue, allowing laser irradiation of the tumor location for PDT
[58].

3.2. Cerasomal porphyrins and cancer photodynamic theranostics

Researchers are studying ways of improving the physical and chemical stability of liposomes [59], to
overcome problems of short shelf-life and the rapid clearance from the blood circulation. Liposomes
with a PEG coating have longer blood circulation times [60], but may have problems with skin toxicity
[61,62] and in addition anti-PEG IgM formation may lead to accelerated blood clearance (ABC).
Moreover, the larger overall size and hydrophilic nature of PEGylated liposomes can decrease the
interaction with cells and prevent the porphyrin uptake into cancer cells [63].
Cerasomes are a new type of hybrid nanoparticle that can be thought of as partially silica-coated
liposomes. Cerasome-forming lipids (CFLs) are composed of three basic components: hydrophobic alkyl
chains, hydrophilic lipid molecules with triethoxysilane headgroups, and a connector unit. The siloxane
coating provides cerasomes with greater mechanical and thermal stability compared to normal
liposomes, and the bi-layer construction makes them less dense and more flexible than silica NPs [64].
Cerasomes can be stored in a water-based solution for months at 4 °C without any change in size [45].
Cerasomes exhibit better biocompatibility than silica NPs due to the liposomal architecture and have
been used as drug delivery systems [65,66]. Liang et al. [67] reported the preparation of porphyrin
containing cerasomes by a sol-gel self-assembly process based on porphyrin-organoalkoxysilylated
lipids. The resulted cerasomes showed good tumor accumulation, better stability, and
enhanced biodistribution. Moreover, the porphyrin molecules still were able to produce singlet oxygen
after irradiation with 400–700 nm light.

3.3. Porphysomes for cancer theranostics

Mineral-based nanoparticles have the potential for nano-oncology, but their possible toxicity is a
source of concern. Multifunctional porphysomes that are derived from porphyrins
and phospholipids have been introduced as photothermal, photodynamic and photoacoustic imaging
agents [[68], [69], [70]] (Fig. 5).

Fig. 5. (a) A typical scheme for porphysome, containing porphyrin and long-chain lipid.
The phospholipid headgroup (red) and porphyrin (blue) are highlighted in the subunit (left) and assembled
nanovesicle (right). (b), Electron micrographs of negatively stained porphysomes (5% PEG–lipid, 95%
pyropheophorbide–lipid). (c), Absorbance of the porphyrin–lipid subunits added in porphysomes formed from
pyropheophorbide (blue), zinc-pyropheophorbide (orange) and bacteriochlorophyll (red) in PBS. (d),
Resonance light scattering spectra ratio between gold nanorods and pyropheophorbide porphysomes. Nanorod
and porphysome concentration was adjusted to have equal optical density at 680 nm. (e), Dynamic light
scattering size profiles of indicated porphysomes recorded in PBS [71].

Porphysomes are another kind of nanocarrier that are produced by self-assembly of porphyrin-lipid
conjugates into bi-layered vesicles. They show fluorescence self-quenching but also specialized
photophysical properties like photoacoustic and photothermal. The sensitive imaging of the lymphatic
system by photoacoustic tomography was made possible by the use porphysomes. When the
porphysomes are biodegraded in the tissue, the fluorescence self-quneching is released, generating
intense near-infrared fluorescence for low-background. fluorescence imaging. Porphysomes have
minimal acute toxicity in mice, up to intravenous doses of 1000 mg kg−1. Tumor xenograft-bearing mice
accumulate porphysomes, allowing photothermal tumor destruction by laser irradiation. Porphysomes
have a multifunctional capability for biophotonic imaging and therapy [70]. They can be used for

fluorescence and spectroscopic tracking, and for photothermal and photodynamic tumor destruction
[[72], [73], [74]]. Porphyrin-containing NPs have a role as agents in techniques like photoacoustic
tomography (also named optoacoustic tomography) [75,76], optical frequency domain imaging [77]
and multifunctional approaches [78]. Another method is quantum dots which function as fluorescent
probes with absorption coefficients of 105-106 M−1cm−1 [79]. Gold NPs have even higher extinction
coefficients (109-1011 M−1cm−1) [80].
Nanospheres, polymersomes, liposomes, lipoproteins, and micelles are all organic NP which have been
used as drug delivery systems with good biocompatibility [[81], [82], [83], [84], [85]]. While organic NPs
cannot generally be used as optical agents, because they lack near-infrared spectral absorption peaks,
when they are combined with porphyrins they often produce self-assembled nanoparticles with high
absorption of light. However these structures are often not suitable as biophotonic probes because of
they lack stability, solubility or biological compatibility [86]. Porphysomes, are self-assembled organic
NPs that also possess liposome-like properties such as the potential to be loaded with drugs, nearinfrared light absorption, fluorescence quenching, and good biocompatibility.
Lysophosphatidyl choline could be conjugated to pyropheophorbide by an acylation reaction, leading
to the production of a supramolecular porphysomes assembly. Two absorption peaks, (400 nm and
680 nm) are seen in pyropheophorbide porphysomes. Another porphyrin structure which is similar
to bacteriochlorophyll, formed porphysomes with an absorption peak about 760 nm. Shifting the
absorption bands (440 nm and 670 nm) is a result of inserting metal ions into the porphyrin-lipid
conjugate, and demonstrated that porphysomes could form metal-chelating bilayer vesicles. In vivo
toxicity studies of porphysomes in mice, showed that after two weeks there were no changes in
hepatic function, endogenous porphyrin metabolism, or the number of white blood cells. They also
reported there were no changes in heart, liver, spleen, lung and kidney tissues, removed at necroscopy
and stained with H&E (hematoxylin and eosin). The properties of porphysomes like, tunable absorption
coefficients and their ability to function as photothermal and photoacoustic sensitizers make them
promising for multimodal imaging and theranostic applications [[87], [88], [89], [90]].
Researchers demonstrated that porphysomes could be utilized for targeted PDT by conjugating folic
acid which is recognized by the folate receptor that is over-expressed in many cancer cell lines
[91,92]. Microbubbles containing porphysomes exhibited multipurpose photoacoustic and ultrasonic
properties, due to their porphyrin-lipid structure containing a gas bubble which could be used
in ultrasound imaging. Researchers have transformed these microbubbles into nanoparticles with
varying (from 5 nm to 500 nm) Instead of drugs releasing. Their small sizes enable better penetration
into tissue but has a negative effect on their acoustic reflectivity. The delivery of drugs can be followed
by image guidance based on ultrasound imaging, and measuring the drug concentration in the tissue
by fluorescence imaging [93]. In another study, Carter et al. [94] modified the porphyrin molecule with
a long chain lipid based on results obtained from molecular dynamics simulation. The results showed
10 mol % porphyrin–phospholipid was sufficient to allow light-trigged membrane permeabilization. Xu
et al. [95] developed a reduced glutathione (GSH)-responsive porphyrin derivative that could form
porphysomes with high DOX loading capacity. The porphysome structure is destroyed upon
penetration into the cell due to the presence of high amounts of GSH. Hence, the DOX drug will be
released, and the fluorescence of the porphyrin will be recovered. Nathan et al. [96] have also shown

that the modification of porphyrins using a l-glutamide lipid chain led to the formation of porphysomes
with better PDT efficiency compared to the usual liposomal formulations.

3.4. Coated membrane NCs for targeted delivery

Nanocarriers (NCs) can be used for targeted delivery of cancer therapy, when they are coated with a
preparation derived from cell membranes (CCMCNCs). Bose et al. reported the preparation of
CCMCNCs, and their direct delivery of therapeutics to cancerous tissue. CCMCNCs are coated with a
variety of molecules such as proteins with different functions, such as recognizing tumor cells,
enhanced adhesiveness, and extended blood circulation times. This allows improved targeting,
increased intra tumoral permeability, and better binding of the NCs to specific tumors [43]. Cells
provide the building blocks of CMCNCs as a hybrid nano-platform containing both synthetic and natural
components [97]. The core has the potential to be loaded with therapeutics, such as genes, drugs, or a
combination of both drugs and genes, as well as imaging agents. Proteolipid structures originating from
cell membranes sources make up the external structure [[98], [99], [100]]. Different combinations
of glycan Q4 structures, proteins and lipids compose these proteolipid structures [101]. In
addition, targeting ligands such as lymphocyte surface receptors (like CD44), immunoglobulin
superfamily members, integrins, cadherins, and selectins can all be incorporated encouraging cellmatrix and cell-cell interactions [102,103].
The well-studied cadherins are protein molecules that participate in cell-cell adhesion, regulation of
genes by bata-catenin pathways, migration of cells, and cell signaling by the EMT (epithelialto mesenchymal transition) [104]. Unlike the cadherins, integrins have roles both in ECM (cellextracellular membrane) and cell-cell interactions, and have tissue-specific and cell-specific functions.
Integrins, such as integrin alpha-1 (ITa1), integrin alpha-2 (ITa2), integrin alpha-5 (ITa5), integrin beta-1
(ITb1), integrin beta-3 (ITb3), integrin beta-4 (ITb4), and integrin beta-5 (ITb5), are widely expressed on
the plasma membrane of different cancer cells [105]. Coating these proteins upon the surface of the
nanocarrier may improve tumor targeting, extend blood circulation time, and reduce toxicity [106].
Nano-theranostics, such as semiconducting QDs (like CdSe), metal-organic frameworks, metallic
nanoparticles (e.g., Au), magnetic nanoparticles (e.g., Fe3O4), are often used in cancer diagnosis and
treatment [4,6,107,108].
Porphyrins can play a role in CCMCNCs as nano-theranostics and nano-therapeutics. Li et al. created a
new biomimetic nano-platform named TPZ@PCN@Mem. It contained the bioreductive drug,
tirapazamine (TPZ) loaded into the porphyrinic metal-organic framework PCN-224 to produce the
CCMCNC for tumor-targeted combination therapy. The TPZ@PCN@Mem nano-theranostic structure
avoided recognition by the immune system, and accumulated inside tumor tissues [109].
TPZ@PCN@Mem produced a massive quantity of ROS (reactive oxygen species) upon laser irradiation
that could destroy cells or tumors. However PDT of hypoxic tumors, can be limited by photochemical
depletion of available oxygen. Tumors that have high metabolism and become hypoxic, adapt by
triggering the Warburg effect [110]. Delivery of the bioreductive drug TPZ allows production of
a cytotoxic agent only when oxygen concentrations are very low [111].
Ying et al. used a “cascade bioreactor” nanoconstruct by incorporated the enzymes glucose
oxidase (GOx) and catalase inside the CCMC porphyrin-based Zr-MOF PCN-224. When the lipid
vesicles were engulfed by the cells, the GOx depleted the glucose stores thus starving the cellular

metabolism, while at the same time the catalase produced oxygen from the hydrogen peroxide formed
in the GOx reaction, thus increasing the oxygen available for singlet oxygen production upon PDT by
laser irradiation [112].

3.5. Virus-like particles (VLPs)

Viral capsids function as non-infectious protein-based nanoparticles – known as VLPs (virus-like
particles) [113]. Although the first oncolytic viral therapy was approved by U.S. FDA, but no recent
virus-derived remedies for delivery of genes have been approved. VLPs have many advantages
including low cost, natural construction, and the potential to carry large amounts of cargo large
compared to other types of NPs. In addition, numerous copies of protein receptors helps VLPs to be
recognized by bacteria and mammalian cells. Also, their encapsulated viral genomes could be useful as
a therapeutic cargo [114,115]. Because VLPs are natural, they provide easy surface functionalization via
different surface chemistry approaches that have been well discussed in the literature [116].
Researchers have suggested that reactive amino acids could be applied to couple the cargo and ligands
either on the inside or the surface of the capsids or VLPs. These VLPs may have lower toxicity than
metal nanoparticles, greater stability compared with liposomes, and are more uniform compared
to polymeric nanoparticles. The delivery efficiency of the vehicles depends on surface
functionalization, and the surface can be decorated with different biomolecules. Also, specific cellular
targeting decreases immune responses, and may potentially encourage extravasation. Many methods
require covalent attachment to either natural or non-natural reactive amino acids (Fig. 6), however,
phage-display technology can allow expression of peptides or proteins by genetic programming of the
primary sequence of amino acids [117,118].

Fig. 6. A different approach for surface modification of VLPs; (a) Primary amines (lysines, N-termini): NHS-ester
conjugation (left, black) is most common. Thioimidate conjugation (green, right) has recently been described
and is based on the reaction of imidoesters. (b) Thiols (cysteines): maleimides are mainly employed for
covalent bonding. Thiols can also form disulfide bonds under mild oxidative conditions. (c) Carboxylic
acids (glutamic acid, aspartic acid): carbodiimide activates the acid to react with primary amines. (d) Phenol
(tyrosine): oxidation of the ligand moiety to diazonium permits for ortho-attachment to the phenol group. (e)
Alkynes (uAA): alkynes react with azides in the presence of Cu(I). (f) P-aminophenylalalnine (uAA): the reaction is
similar to that displayed with tyrosine (d), but remains completely orthogonal. (g) Azides (uAA): azides can
undergo the Staudinger ligation (left, green), Cu(I)-catalyzed click chemistry (e) or Copper-free click chemistry
(black, right). The Staudinger ligand has fallen out of favor because of kinetic limitations and has not recently
been utilized for VNP functionalization. The reaction of the cyclooctyne or other copper-free click chemistry
reagent has yet to be ascertained employing VNPs and is displayed only to conceptualize how click chemistry
can become copper-free [116].

One type of cargo that can be loaded into VLPs is small molecules, and porphyrins fall into this category
[16,119]. This approach involves both covalent and non-covalent methods. Non-covalent approaches
do not require chemistry, while covalent approaches have the benefit of efficient encapsulation and
stability of the loaded cargo. VLPs derived from plant-based viruses are considered to be safer than
those from animal-based viruses. A CCMV preparation was loaded with polystyrene sulfonate by noncovalent electrostatic interaction with coat proteins [120,121]. Fluorescent probes and antibiotics have
been non-covalently connected to CPMV using small molecules that bind to the RNA genome by
electrostatic interactions [122]. However, there are difficulties in loading and preserving these small
cargoes [123,124]. Non-covalent loading of photosensitizers into VLPs has been used to develop

multifunctional nanoconstructs. For example, Masarapu et al. [125] used the Physalis mottle virus
(PhMV) coat protein, which was expressed in Escherichia coli to develop VLPs. Then,
doxorubicin, rhodamine B or Zn-EpPor molecules were loaded as a chemotherapeutic drug, fluorescent
compound, or photosensitizer to make multifunctional VLPs. The covalent approach is of interest due
to the stronger binding between the photosensitizer molecules and the ligands in the VLP. For
example, Rhee et al. [126] first synthesized an azide-tailed metalloporphyrin derivative and used clickchemistry to attach it to the ligands of bacteriophage Qβ VLP as a functionalized glycan to be used for
specific PDT of cells bearing the CD22 receptor.

3.6. Stem cells and extracellular vesicles

Mesenchymal stem cells (MSCs) could be used as nanocariers of drug molecules due to: 1) ability to be
isolated from the bone marrow or other tissue of patients [127,128]; 2) ability to be further
functionalized chemically or genetically to enhance their selectivity [129]; 3) good biocompatibility and
avoidance of immune rejection by the body [130]; and 4) high tumor affinity with long retention time
in tumors in-vivo [131,132]. Porphyrin-lodad MSCs have also been applied for delivery of porphyrins as
photosensitizers into cancer cells for photodynamic therapy. Cao et al. [133] loaded hydrophobic
purpurin-18 (PP-18) molecules into silica nanoparticles (SNPs), and the PP-18-SNPs were later loaded
into MSCs. The designed PP-18-SNPs-MSCs were used for in-vitro PDT of breast cancer cells and for invivo PDT of breast tumors in rats. In another study, porphyrin molecules were first loaded into
fluorescent dye-labeled poly-methyl methacrylate (PMMA) nanoparticles, and then loaded into MSCs.
The obtained nanocarriers were used for successful simultaneous fluorescence imaging and invitro PDT of osteosarcoma [134].
Extracellular vehicle (EVs) are cell-derived membrane vesicles that can penetrate cells via an
endogenous mechanism. EVs are capable of functionally transferring biological information, and since
this discovery, the potential use of EVs as carriers for drug delivery has attracted scientific interest. EVs
may have several benefits over other drug delivery carriers, such as their ability to overcome natural
barriers, inherent cell targeting properties, and stability in the circulation. However, because of the
lack of methods for scalable isolation of EVs and their efficient loading with drugs, the applications of
EVs as drug delivery systems has been limited. Furthermore, their inherent cell targeting features could
be improved via EV engineering in order to accomplish better targeted drug delivery [135,136]. Vader
et al. [137] reported the possibility of loading EVs with large proteins, but it is yet to be ascertained
how their immunogenicity is affected by the sonication or separation processes, or
by saponin treatment. Fuhrmann et al. carried out a comparison of strategies for loading hydrophilic
and hydrophobic porphyrins into EVs, and compared these to free drug or porphyrin-loaded liposomes
in terms of cellular uptake. Treating cancer cells with porphyrin loaded EVs followed by irradiation
showed reductions cell viability. Nevertheless, finding the most suitable approach for clinical use is yet
to be determined [138,139].

3.7. Porphyrin polymeric nanoparticles

Polymerization of porphyrins is another approach to enhance their therapeutic effects and overcome
some common drawbacks of porphyrins (i.e., their low absorption coefficients, poor water-solubility,
and leaching from delivery carriers). The polymerization of porphyrins (i.e., introducing porphyrins into
the polymer backbone) could modulate the HOMO-LUMO energy bandgap and, consequently change

the balance between radiative decay rate, non-radiative-decay rate and intersystem crossing rate in
the excited porphyrin molecules [140,141]. Therefore, porphyrin-based conjugated polymers could
serve as theranostic materials with light-harvesting properties and enhanced efficiency in either
photodynamic therapy (PDT) or photothermal therapy (PTT) as well as NIR fluorescence emission.
For example, Wu and Xu reported that a >9-fold enhancement of emission after one-photon excitation
(at 380 nm) and 30-fold enhancement after two-photon excitation (at 800 nm) were observed for an
anionic hematoporphyrin (HP) electrostatically conjugated to a cationic conjugated polymer (PFB) due
to the occurrence of FRET from PFB to HP [142]. In another study, Xing et al. [143] reported that a
block-co-polymer containing cationic conjugated polythiophene and porphyrin could carry out
simultaneous fluorescence imaging and in-vitro PDT of pulmonary adenocarcinoma cells (A549) and
renal cell carcinoma (A498). Cheng et al. [144] synthesized polymer-dots containing a co-polymer
of polyfluorene derivative (PFBT) and tetraphenylporphyrin (TPP). These polymer-dots showed bright
fluorescence with a good singlet oxygen quantum yield for image-guided PDT of xenograft tumors in
Balb/c nude mice. As mentioned above, non-radiative decay rates could also be modulated through
polymerization of the porphyrins. In order to further increase the non-radiative rate, a donor-acceptor
pair contained in a structured porphyrin-conjugated polymer was reported by Guo et al. [145] for
efficient PTT in vitro and in vivo. The D–A structure introduced intramolecular charge transfer along the
backbone, resulting in broadened absorption peaks, red-shifted Q band, and increased extinction
coefficient (4.23 × 104 mol−1cm−1 at 800 nm) as compared to the porphyrin photothermal agent alone.

4. Microporous organic polymers

In recent decades, microporous organic polymers (MOPs) with high surface area have been
investigated in some industrial processes, such as gas absorption, catalysis, electronics, and recently
for controlled drug release [146,147]. Covalent organic frameworks (COFs) and metal-organic
frameworks (MOFs) are crystalline hybrid MOPs. In COFs the organic ligands are covalently bonded to
each other [148,149], while in MOFs polydentate organic linkers are coordinated to transition metal
cations [[150], [151], [152]]. Both COFs and MOFs have been extensively used as nanocarriers for
different biomedical applications [153,154]. In particular, porphyrins-loaded COFs and MOFs are
discussed in the following section.

4.1. Covalent-organic frameworks (COFs)

COFs have been used to deliver porphyrin molecules into cancer cells and tumors, and have shown
enhanced therapeutic efficiency compared to free porphyrins. For example, Tao et al. [155]
synthesized fluorinated COFs by crosslinking the photosensitizer meso-5, 10, 15, 20-tetra (4hydroxylphenyl) porphyrin (THPP) with poly (ethylene glycol) (PEG) and perfluoro-sebacic acid (PFSEA)
via a one-pot esterification. The developed porphyrin-loaded COFs were used for
simultaneous oxygenation and PDT of solid tumors. Another porphyrin-COF nanocomposite was
synthesized using 5,10,15,20-tetrakis (4-aminophenyl)porphine (Tph) and 2,5-dihydroxy-1,4benzenedicarboxaldehyde (Dha). The obtained porphyrin-loaded COF nanoparticles possessed high
photothermal conversion efficiency (21.7%) with a good singlet oxygen quantum yield, and were used
for simultaneous PTT (at 808 nm) and PDT (at 650 nm) of HeLa cancer cells [156]. Recently, 3-D
porphyrin-based COFs were synthesized by Lin et al. [157]. They found that the microporous

material possessed a high surface area and could generate singlet oxygen, while metalation of the
porphyrin rings caused a decrease in its photosensitization ability.
Covalent triazine frameworks (CTFs) are members COFs with triazine unit, with exceptional porosity,
good chemical stability, and can be fabricated with both crystalline and amorphous constructions
[158]. Luo et al. investigated two porphyrin-based porous covalent bonded triazine frameworks
(PCTFs). The porphyrin was attached using the Friedel–Crafts reaction. The CTFs possessed a large
Brunauer–Emmett–Teller surface area (up to 1089 m2 g−1 area) and absorbed CO2 up to 139.9 mg g−1 at
273 K/1.0 bar. They also had selective absorption of CO2/CH4 up to 6.1 mg g−1 at 273 K/1.0 bar. The
researchers described new attempts to produce porphyrin-based covalent bond triazine frames
(PCTFs) using a single-step Friedel–Crafts reaction with (NCCl)₃ and a tetra-reactive 5, 10, 15, 20tetraphenylporphyrin (TPP). (NCCl)₃ was used as an electron-deficient monomer for the
polymerization, and the porphyrin nucleus provided a coordination site for metal ions [146]. PCTF
drugs have a large surface area and the capacity for CO2 absorption, good drug loading, and tailorable
drug release (Fig. 7). The reaction needs only moderate conditions without poisonous or costly
catalysts, to reduce the expense for construction of novel MOPs. The chemical composition of PCTFs
was proved by spectral characterization (FTIR and 13C NMR). For FTIR spectra, the bands appeared at
1620 and 1400 cm−1 assigned to the quadrant and stretching of the semicircular triazine ring, in line
with pervious reports [146]. There was a peak near 800 cm−1 for the ring of para-substituted benzene.
In PCTF the Mn-porphyrin showed a peak at 1040 cm2 for the N–Mn in-plane bending. These porous
PCTFs have the potential to be used as drug carriers in biomedical applications [159].

Fig. 7. Schematic demonstration of the PCTF and PCTF-Mn producing [146].

Recently, a porphyrin nanocage-embedded polymer was synthesized as single molecule nanoparticles
(34.6 ± 1.8 nm by dynamic light scattering) and used for fluorescence imaging (red emission with a
quantum yeild of 6.9% in water) of U87MG cells, and was also labeled by radioactive 64Cu for positron
emission tomography (PET) imaging. They were able to monitor the
delivery, pharmacokinetic behavior, biodistribution, and excretion of the nanoparticles in animal
models in real time [160].

4.2. Metal-organic frameworks (MOFs)

Metal–metalloporphyrin frameworks (MMPFs) are a new class of nanomaterials that have received
much attention due to their versatile functionality. The MMPFs compose a coordination that can be
custom-designed metalloporphyrin ligands. The porphyrin core enables the synthesis of different types

of metalloporphyrin cores via a metalation process. The MMPFs could be synthesized via different
approaches. The direct synthesis approach includes crystal engineering [161,162], pillared-layer
strategy [163,164], nanoscopic metal–organic polyhedrons (MOP) [[165], [166], [167]], and indirect
synthesis based on the post-modification of the MOFs based on porphyrin-based ligands [168,169].
Numerous studies have been done on metallic-organic frameworks as carriers of drugs, especially
porphyrin-based compounds, for biomedical applications
[[170], [171], [172], [173], [174], [175], [176], [177], [178]]. For example, Zheng et al. [179] reported
the synthesis of a metal-organic framework@porous organic polymer (MOF@POPs) using a postmodification approach which is illustrated in Fig. 8. The synthesized MOF@POP with a size of 165 nm
showed better PDT effects compared to the porphyrin-loaded POPs alone. The PDT application of
MOF-based porphyrins is not limited to colloidal system. Zhou et al. [180] developed a thin polymer
using a MOF-templating approach which contained porphyrin molecules and showed PDT effects
against E. coli.

Fig. 8. (a) the MOF@POPs based on UiO-AM and polyaniline as MOF and porous organic polymer,
respectively [179] and (b) Developing water-soluble MOF-templated porphyrin polymer thin film with
high PDT effect against bacteria [180].

A key factor in the effective delivery of MOF-based porphyrin nanocomposites is surface modification,
which leads to the targeted delivery of the nanocomposites. MOF UiO-66 is a zirconium terephthalate
which can be loaded with cargo, forming ~200 nm coated nanoparticles synthesized by functionalized
linkers, and covalently surface modified using mild reactions to attach chains of poly (ethylene glycol)
(PEG). At pH 7.4 the PEG chains provide enhanced stability to phosphates and overcome the ‘‘burst
release’’ phenomenon, while at pH 5.5, stimuli-responsive drug release is achieved. Furthermore, the
cellular uptake is governed by the NP surface chemistry, so that PEGylated UiO-66 escapes lysosomal
degradation [181].
Moreover, MOF nanoparticles with attached polymer chains such as polyaniline-modified UiO-66 could
be used in anticancer photothermal therapy [182]. Zr porphyrin-based MOFs formed 90 nm diameter
NPs that were taken up by HeLa cells [36]. The versatility of the click assembly protocol could help a
variety of MOFs to show selective cell targeting [183].
A discrete organoplatinum (II) metallocage was recently reported by Yu et al. [184]. They used the
chemotherapeutic drug cis-(PEt3)2 Pt (OTf)2 as a building block to construct this metallocage to be
loaded with porphyrin molecules. This new design prevented the aggregation of the porphyrins (i.e.,
due to π-π stacking) and improved the singlet oxygen quantum yeild. The metallocage-loaded NPs
showd tri-modal functionality, and could be used for simultaneous fluorescence imaging (red
emission), chemotherapy and PDT.

5. Porphyrin-based nanomaterials combined with other therapeutic methods
5.1. Chemotherapy

Bioluminescence and fluorescence imaging can be used to monitor drug release using advanced
theranostic techniques. Fluorescence imaging reporters over a wide spectral range can be incorporated
into the nanoplatforms. A bi-functional fluorescence and anti-tumor drug delivery system was
produced by encapsulating doxorubicin (DOX) inside the hydrogel formed from porphyrins with a fourarm copolymer of PEG-PCL as a drug carrier. The imaging ability was improved because the drug and
the fluorescence signals were separated via the hydrogel. The inhibition of tumor growth could be
followed through bioluminescence imaging [185,186]. Other researchers have prepared fluorescent
copolymers to overcome the shortage of fluorescent porphyrin-compounds [187]. In vivo fluorescence
imaging with the four-arm PEG-PCL copolymer (POR-PEG-PCL) demonstrated that the porphyrinhydrogel could be used as an implant as a systemically administered nanogel-probe [187]. The PORPEG-PCL hydrogel functioned as a drug carrier for Dox anti-tumor drug delivery which is a dual
fluorescent therapeutic nanosystem. Other fluorescent drug delivery systems have been monitored
using rhodamine to monitor the biodistribution after intratumoral injection [188]. Tumors that have
been stably transfected with the luciferase enzyme were grown in the liver of tumor of nude
mice were used for dual bioluminescence and multispectral fluorescence imaging to follow the tumor
response in real-time [189]. Hydrogels are increasingly being used for drug delivery or as tissue
engineering platforms [190,191].
Bera et al. reported a novel nanocarrier based on the tetrasodium salt of meso-tetrakis (4sulfonatophenyl)porphyrin (TPPS) attached to gold nanoparticles (TPPS-AuNPs). The nanocarrier was
loaded with the antitumor drug doxorubicin (DOX) and was selectively internalized by tumor cells

compared to normal cells. The attachment of TPPS onto the gold nanosurface provided excellent
stability and biocompatibility. Porphyrin interacted with the gold nanosurface forming a strong
association complex. DOX-loaded nanocomposite (DOX@TPPS-AuNPs) demonstrated enhanced cellular
uptake with significantly reduced drug efflux in MDR brain cancer cells, with increased retention time.
It caused 9 times greater apoptosis via triggered release at acidic pH. DOX was loaded on the
porphyrin-modified gold NPs with high encapsulation efficacy (~90%) but was capable of releasing
~81% of DOX at low-pH. DOX-loaded TPPS-AuNPs exhibited higher inhibition of cellular metastasis,
invasion, and angiogenesis [192].

5.2. Radiotherapy

Radiotherapy (RT) is an efficient method to treat many types of cancer. However, debilitating side
effects are often observed due to high X-ray doses (50–75 Gy). To overcome this limitation, developing
new therapeutic nanomaterials with dual-functional capability could be a new strategy
[[193], [194], [195], [196]]. Recently, radiotherapy agents based on porphyrin co-loaded nanomaterials
have received attention due to the possibility of simultaneous radiotherapy and radiodynamic therapy
of different cancers. For example, a nanoscale MOF was developed using either Hf12 or Hf6 secondary
building units (SBUs) and Ir (2,2′-bipyridine)[2-(2,4-difluorophenyl)-5 (trifluoromethyl)pyridine]2+ based
ligands. This nanoscale MOF showed efficient production of hydroxyl radicals as well as singlet oxygen
and superoxide anions under X-irradiation and carried out radiotherapy and radiodynamic therapy
[197]. The same group developed another nanoscale MOF based on Hf-DBB-Ru [DBB-Ru = bis (2,2′bipyridine)(5,5′-di (4-benzoato)-2,2′-bipyridine) ruthenium (II) chloride], whiche could target the
mitochondria of MC38 cells. The designed nanomaterial showed both radiotherapy and radiodynamic
therapy effects due to efficient generation of hydroxyl radicals (i.e., by Hf6 SBUs) and singlet oxygen
(i.e., by DBB-Ru photosensitizers) [198]. A similar concept was also applied to prepare an indoleamine
2,3-dioxygenase inhibitor-loaded nanoscale MOF to enhance checkpoint blockade immunotherapy. It
has been proposed that nanoscale MOFs could be utilized for delivery of different therapeutic agents,
such as porphyrin and radiotherapy agents than could effectively kill cancer cells via a combination of
different modalities. These structures could be further modified with other therapeutic agents for
developing newer generations of therapeutic nanomaterials.

6. Porphyrin-based nanomaterials combined with magnetic resonance
imaging

Porphyrin molecules and magnetic-resonance agents could be loaded into the nanocarrier and provide
a dual-functional theranostic nanomaterial. As an example, Mn(III)- meso-tetrakis (4sulphonatophenyl) porphyrin (Mn(III)-TPPS) was loaded on hydrophiobic polymethyl
methacrylate nanoparticles with further surface modification with anionic molecules for simultaneous
sonodynamic therapy and MRI imaging of rat breast tumor. The ROS generation initiated by irradiation
of shock waves and MRI enabled to monitor the tumor size and treatment progress [199].

7. Conclusions and future work

Porphyrins display good photochemical properties, especially singlet oxygen generation, which makes
them a suitable candidate for PDT. However, porphyrins suffer from low water-solubility. Hence,
efficient delivery of porphyrins requires a proper nanoscale formulation. Therefore, different types of

nanoparticles have been proposed to transport the hydrophobic porphyrin molecules in biological
media. Moreover, other nanocarriers such as metal-organic frameworks and extracellular vesicles are
of increasing interest.
Furthermore, porphyrins undergo an aggregation-caused quenching (ACQ) effect which quenches their
photophysical properties such as fluorescence and singlet oxygen generation, when the local
concentrations reaches a certain level and they become aggregated. To address this issue, porphyrinbased aggregation-induced emission (AIE) dyes have been developed and investigated [189,200,201].
These AIE dyes are not emissive in their individual solubilized molecular state, but their fluorescence is
turned on in an aggregated state. This property makes them suitable for high loading into different
nanocarriers. Hence, it is expected that by a combination of porphyrins and AIE-active moieties, a new
generation of porphyrins with a variety of properties suitable for bioapplications such as fluorescence
imaging, photoacoustic imaging (PA), magnetic resonance imaging (MRI), photodynamic therapy
(PDT), photothermal therapy (PTT), and recently radiotherapy (RT) and radiodynamic therapy (RDT)
could be produced.
The multifunctional nature of porphyrins and their derivatives is expected to play a vital role in future
clinical therapy. The deep exploitation of novel porphyrins and their derivatives has recently gained
increasing scientific interest. Developing new porphyrins with different properties is of importance for
many bioapplications.
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